GSK Japan Looking to Develop Otilimab for COVID-19; President Stresses Efforts on Vaccines, Disease Management Too

GSK Japan President Paul Lirette GlaxoSmithKline hopes to develop its experimental rheumatoid arthritis (RA) drug otilimab for the treatment of COVID-19 in Japan as well as in other countries, with discussions with local regulators already underway, the company’s Japan chief...read more